# nature portfolio

Corresponding author(s): Craig Mortimer

Last updated by author(s): 22/05/24

# **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

#### Statistics

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
X		The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
X		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
X		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
X		A description of all covariates tested
X		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
X		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
X		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable</i> .
X		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
X		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
X		Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

#### Software and code

Policy information about availability of computer code		
Data collection		
Data analysis		

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

#### Research involving human participants, their data, or biological material

Policy information about studies with <u>human participants or human data</u>. See also policy information about <u>sex, gender (identity/presentation)</u>, <u>and sexual orientation</u> and <u>race, ethnicity and racism</u>.

Reporting on sex and gender	Reported within the Sample Outline to show that data was not unilaterally collected.
Reporting on race, ethnicity, or other socially relevant groupings	Given the focus of the study this data was not deemed relevant.
Population characteristics	Clinical levels noted in the Sample Outline to demonstrate experience of participants.
Recruitment	Recruited from the same organsiation and open to all paramedics.
Ethics oversight	Provided through the HRA and Kingtston University, London.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

# Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

🗌 Life sciences 🛛 🛛 🛛 Behavioural & social sciences 📄 Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	
Data exclusions	
Replication	
Randomization	
Blinding	

### Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	Qualitative study looking at the clinical reasoning of Paramedics treating acute asthma exacerbations
Research sample	15 Paramedics
Sampling strategy	Purposeful Sampling
Data collection	Semi-Structured Interviews
Timing	Over 8 months
Data exclusions	None
Non-participation	All vouInteers were included within the study
Randomization	Convenience sampling negates this need

th

# Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description		
Research sample		
Sampling strategy		
Data collection		
Timing and spatial scale		
Data exclusions		
Reproducibility		
Randomization		
Blinding		
Did the study involve field work? Yes No		

#### Field work, collection and transport

Field conditions	
Location	
Access & import/export	
Disturbance	

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems		Methods	
n/a	Involved in the study	n/a	Involved in the study
$\boxtimes$	Antibodies	$\boxtimes$	ChIP-seq
$\boxtimes$	Eukaryotic cell lines	$\mathbf{X}$	Flow cytometry
$\mathbf{X}$	Palaeontology and archaeology	$\boxtimes$	MRI-based neuroimaging
$\mathbf{X}$	Animals and other organisms		
$\mathbf{X}$	Clinical data		
$\mathbf{X}$	Dual use research of concern		
$\mathbf{X}$	Plants		

#### Antibodies

Antibodies used
Validation

#### Eukaryotic cell lines

Policy information about cell lines and Sex and Gender in Research			
Cell line source(s)			
Authentication			
Mycoplasma contamination			
Commonly misidentified lines (See ICLAC register)			
(See <u>reprice</u> reprice)			

#### Palaeontology and Archaeology

Specimen provenance		
Specimen deposition		
Dating methods		
Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.		
Ethics oversight		
Note that full information on the approval of the study protocol must also be provided in the manuscript		

#### Animals and other research organisms

Policy information about studies involving animals; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in</u> <u>Research</u>

Laboratory animals	
Wild animals	
Reporting on sex	
Field-collected samples	
Ethics oversight	

Note that full information on the approval of the study protocol must also be provided in the manuscript.

#### Clinical data

Policy information about <u>clinical studies</u>

Clinical trial registration	
Study protocol	
Data collection	
Outcomes	

#### Dual use research of concern

Policy information about <u>dual use research of concern</u>

#### Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No	Yes
	Public health
	National security
	Crops and/or livestock
	Ecosystems
	Any other significant area

#### Experiments of concern

Does the work involve any of these experiments of concern:

No	Yes
	Demonstrate how to render a vaccine ineffective
	Confer resistance to therapeutically useful antibiotics or antiviral agents
	Enhance the virulence of a pathogen or render a nonpathogen virulent
	Increase transmissibility of a pathogen
	Alter the host range of a pathogen
	Enable evasion of diagnostic/detection modalities
	Enable the weaponization of a biological agent or toxin
	Any other potentially harmful combination of experiments and agents

#### Plants

Seed stocks	
Novel plant genotypes	
Authentication	

#### ChIP-seq

#### Data deposition

Confirm that both raw and final processed data have been deposited in a public database	e such as GEO.

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links May remain private before publica	tion.
Files in database submissio	n
Genome browser session (e.g. <u>UCSC</u> )	
Methodology	
Replicates	
Sequencing depth	
Antibodies	
Peak calling parameters	
Data quality	
Software	

# nature portfolio | reporting summary

#### Flow Cytometry

#### Plots

Confirm that:

The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

All plots are contour plots with outliers or pseudocolor plots.

A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

Sample preparation	
Instrument	
Software	
Cell population abundance	
Gating strategy	

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

#### Magnetic resonance imaging

Specify type of analysis: 🗌 Whole brain

#### Experimental design

Design type	
Design specifications	
Behavioral performance measures	
Imaging type(s)	
Field strength	
Converse 9 imaging perometers	
Sequence & imaging parameters	
Area of acquisition	
Diffusion MRI Used	Not used
Preprocessing	
Preprocessing software	
Freprocessing software	
Normalization	
Normalization template	
Noise and artifact removal	
Volume censoring	
Statistical modeling & inference	
Model type and settings	
Effect(s) tested	

Both

ROI-based

Statistic type for inference	
(See <u>Eklund et al. 2016</u> )	
Correction	
Models & analysis	
n/a   Involved in the study	
Functional and/or effective	e connectivity
Graph analysis	
Multivariate modeling or p	redictive analysis
Functional and/or effective conn	lectivity
Graph analysis	
Multivariate modeling and predi	ctive analysis

This checklist template is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license, usit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>

